Health Care [ 2/12 ] | Pharmaceuticals [ 27/74 ]
NYSE | Common Stock
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications.
Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM.
The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia.
In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer.
Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer.
It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies.
The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer.
The company was formerly known as Bristol-Myers Company.
The company was founded in 1887 and is headquartered in Princeton, New Jersey.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jul 29, 26 | 2.04 Increased by +39.73% | 1.59 Increased by +28.30% |
| Apr 29, 26 | 1.58 Decreased by -12.22% | 1.42 Increased by +11.27% |
| Feb 4, 26 | 1.26 Decreased by -24.55% | 1.20 Increased by +5.00% |
| Oct 29, 25 | 1.63 Decreased by -9.44% | 1.52 Increased by +7.24% |
| Jul 30, 25 | 1.46 Decreased by -29.47% | 1.10 Increased by +32.73% |
| Apr 23, 25 | 1.80 Increased by +140.91% | 1.50 Increased by +20.00% |
| Feb 5, 25 | 1.67 Increased by +5.03% | 1.47 Increased by +13.61% |
| Oct 30, 24 | 1.80 Decreased by -10.00% | 1.50 Increased by +20.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 29, 26 | 12.97 B Increased by +5.74% | 3.32 B Increased by +153.21% | Increased by +25.57% Increased by +139.47% |
| Mar 30, 26 | 11.49 B Increased by +2.57% | 2.68 B Increased by +9.00% | Increased by +23.30% Increased by +6.27% |
| Dec 30, 25 | 12.50 B Increased by +1.30% | 1.09 B Increased by +1.41 K% | Increased by +8.69% Increased by +1.39 K% |
| Sep 29, 25 | 12.22 B Increased by +2.77% | 2.20 B Increased by +81.75% | Increased by +18.01% Increased by +76.84% |
| Jun 29, 25 | 12.27 B Increased by +0.56% | 1.31 B Decreased by -22.02% | Increased by +10.68% Decreased by -22.46% |
| Mar 30, 25 | 11.20 B Decreased by -5.60% | 2.46 B Increased by +120.62% | Increased by +21.93% Increased by +121.84% |
| Dec 30, 24 | 12.34 B Increased by +7.54% | 72.00 M Decreased by -95.91% | Increased by +0.58% Decreased by -96.20% |
| Sep 29, 24 | 11.89 B Increased by +8.44% | 1.21 B Decreased by -37.19% | Increased by +10.18% Decreased by -42.08% |